Filed pursuant to Rule 424(b)(3)
Registration No. 333-226239
PROSPECTUS SUPPLEMENT NO. 5
(To
Prospectus dated August 8, 2018)
INTELLIPHARMACEUTICS INTERNATIONAL INC.
6,858,334 Common Shares
This
Prospectus Supplement No. 5 (this “Prospectus Supplement”) amends and supplements our
Prospectus dated August 8, 2018, as supplemented by prospectus
supplement no. 1, dated August 15, 2018, as supplemented by
prospectus supplement no. 2, dated September 11, 2018, as
supplemented by prospectus supplement no. 3, dated September 13,
2018, and as supplemented by prospectus supplement no. 4, dated
October 1, 2018 (the “Prospectus”), which form a part of our
Registration Statement (our “Registration Statement”) on Form F-1 (Registration No.
333-226239). This Prospectus Supplement is being filed to amend and
supplement the information included or incorporated by reference in
the Prospectus with the information contained in this Prospectus
Supplement. The Prospectus and this Prospectus Supplement relate to
the resale, from time to time, of up to 6,858,334 common shares by
certain of our shareholders identified in the
Prospectus.
This
Prospectus Supplement includes information from our Report on Form
6-K, which was filed with the Securities and Exchange Commission on
October 5, 2018.
This
Prospectus Supplement should be read in conjunction with the
Prospectus that was previously filed, except to the extent that the
information in this Prospectus Supplement updates and supersedes
the information contained in the Prospectus.
NEITHER THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE
“SEC”) NOR ANY STATE SECURITIES COMMISSION OR CANADIAN
SECURITIES REGULATOR HAS APPROVED OR DISAPPROVED OF THESE
SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR
COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL
OFFENSE.
_______________
The
date of this Prospectus Supplement is October 5, 2018
As
previously announced, on April 7, 2017, Intellipharmaceutics
International Inc. (the “Company”) received notice that
Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F.
Laboratories, Inc., Rhodes Technologies, and another party had
commenced patent infringement proceedings against the Company in
the U.S. District Court for the District of Delaware in respect of
the Company’s new drug application filing for Oxycodone ER. A
trial date was set for October 22, 2018.
On
October 4, 2018, the parties to the case mutually agreed to
postpone the scheduled court date pending a case status conference
scheduled for December 17, 2018.